RadiopharmaceuticalFDA-approvedSecond-line
Lutetium Lu 177 vipivotide tetraxetan
Generic name: lutetium lutetium-177 vipivotide tetraxetan
How it works
Delivers radioactive lutetium to prostate cancer cells, causing cell death through radiation damage.
Cancer types
Efficacy
Studies show that lutetium Lu 177 vipivotide tetraxetan can slow disease progression and improve survival in patients with advanced prostate cancer.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing ONC-392 and Lutetium Lu 177 Vipivotide Tetraxetan in Prostate Cancer | Prostate Cancer | phase-1 | — | Source → |
| New Treatment for Advanced Prostate Cancer Uses Targeted Radiation | Prostate Cancer | phase-3 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.